Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (1-10 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|January 1, 1993
Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharidesJ M Walenga
Current Opinion in Pulmonary Medicine|July 1, 1997
Current status on new anticoagulant and antithrombotic drugs and devicesJ M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|April 1, 1985
Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharideJ M Walenga, J Fareed
International Journal of Clinical Practice|June 30, 2010
Drug and dietary interactions of the new and emerging oral anticoagulantsJ M Walenga, C Adiguzel
Clinics in Laboratory Medicine|December 1, 1994
Automation and quality control in the coagulation laboratoryJ M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1983
Current trends in hemostatic testingJ Fareed, J M Walenga
The Medical Clinics of North America|July 1, 1998
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapyJ M Walenga, R L Bick
Journal of Thrombosis and Haemostasis : JTH|January 22, 2015
Complexes of platelet factor 4 and heparin activate Toll-like receptor 4M M Prechel, J M Walenga
International Angiology : a Journal of the International Union of Angiology|April 3, 2012
Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology J Harenberg, E Kalodiki, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Protamine sulfate neutralization of lactobionic acid amidesD Hoppensteadt, J M Walenga, J Fareed
Pageof 20

Showing results (1-10 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|January 1, 1993
Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharidesJ M Walenga
Current Opinion in Pulmonary Medicine|July 1, 1997
Current status on new anticoagulant and antithrombotic drugs and devicesJ M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|April 1, 1985
Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharideJ M Walenga, J Fareed
International Journal of Clinical Practice|June 30, 2010
Drug and dietary interactions of the new and emerging oral anticoagulantsJ M Walenga, C Adiguzel
Clinics in Laboratory Medicine|December 1, 1994
Automation and quality control in the coagulation laboratoryJ M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1983
Current trends in hemostatic testingJ Fareed, J M Walenga
The Medical Clinics of North America|July 1, 1998
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapyJ M Walenga, R L Bick
Journal of Thrombosis and Haemostasis : JTH|January 22, 2015
Complexes of platelet factor 4 and heparin activate Toll-like receptor 4M M Prechel, J M Walenga
International Angiology : a Journal of the International Union of Angiology|April 3, 2012
Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology J Harenberg, E Kalodiki, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Protamine sulfate neutralization of lactobionic acid amidesD Hoppensteadt, J M Walenga, J Fareed
Pageof 20